Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma

Neoplasma

Volumn 53, Issue 3, 2006, Pages 253-258

  Wrobel T ^a   Poreba, M ^a   Mazur, G ^a   Poreba, R ^a   Pyszel, A ^a   Beck, B ^a   Steinmetz Beck, A ^a   Andrzejak, R ^a   Kuliczkowski, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

bFGF; D dimer; Fibrinogen; Non Hodgkin's lymphoma; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; D DIMER; FIBRINOGEN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

EID: 33744905366     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
2. ANSELL SM, ARMITAGE J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1087-1097.
3. SALVEN P, ORPANA A, TEERENHOVI L, JOENSUU H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
4. WOJTUKIEWICZ MZ, RUCINSKA M, ZIMNOCH L, JAROMIN J, PIOTROWSKI Z et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000; 97: 335-342.
5. BEER JH, HAEBERLI A, VOGT A, WOODTLI K, HENKEL E et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002; 88: 745-749.
6. PULANIC D, RUDAN I. The past decade: fibrinogen. Coll Antropol 2005; 29: 341-349.
7. PALUMBO JS, KOMBRINCK KW, DREW AF, GRIMES TS, KISER JH et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309.
8. WOJTUKIEWICZ MZ, SIERKO E, KLEMENT P, RAK J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-384.
9. HARRIS NL, JAFFE ES, DIEBOLD J, FLANDRIN G, MULLER-HERMELINK HK et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting. Airlie House, Virginia. November 1997. Histopathology 2000; 36: 69-86.
10. RAK J, KLEMENT G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000; 19: 93-96.
11. FALANGA A, DONATI MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001; 73: 137-144.
12. FUKAO H, UESHIMA S, OKADA K, MATSUO O. The role of the pericellular fibrinolytic system in angiogenesis. Jpn J Physiol 1997; 47: 161-171.
13. THOMPSON WD, SMITH EB, STIRK CM, MARSHALL FI, STOUT AJ et al. Angiogenic activity of fibrin degradation products is located in fibrin fragment. Eur J Pathol 1992; 168: 47-53.
14. VACCA A, RIBATTI D, RUCO L, GIACCHETTA F, NICO B et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965-970.
15. BERTOLINI F, PAOLUCCI M, PECCATORI F, CINIERI S, AGAZZI A et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
16. SASE T, WADA H, YAMAGUCHI M, OGAWA S, KAMIKURA Y et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 1-2.
17. SORENSEN HT, MELLEMKJAER L, OLSEN JH, BARON JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
18. RICKLES FR, PATIERNO S, FERNANDEZ PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.
19. PINEDO HM, VERHEUL HM, D'AMATO RJ, FOLKMAN J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
20. CHEN J, BIERHAUS A, SCHIEKOFER S, ANDRASSY M, CHEN B et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 334-345.
21. SHOJI M, HANCOCK WW, ABE K, MICKO C, CASPER KA et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
22. MECHTCHERIAKOVA D, WLACHOS A, HOLZMULLER H, BINDER BR, HOFER E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999; 93: 3811-3823.
23. VERHEUL HM, JORNA AS, HOEKMAN K, BROXTERMAN HJ, GEBBINK MF et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-4221.
24. MANDRIOTA SJ, PEPPER MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997; 110: 2293-2302.
25. KROON ME, KOOLWIJK P, VERMEER MA, VAN DER VECHT B, VAN HINSBERGH VW. Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation. Thromb Haemost 2001; 85: 296-302.
26. PEPPER MS, FERRARA N, ORCI L, MONTESANO R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-906.
27. TSENG CS, LO HW, CHEN PH, CHUANG WL, JUAN CC et al. Clinical significance of plasma D-dimer and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology 2004; 51: 1454-1458.
28. MATSUYAMA W, HASHIGUCHI T, MIZOGUCHI A, IWAMI F, KAWABATA M et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118: 948-951.
29. ZACHARY I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280: C1375-1386.
30. LI W, KELLER G. VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J Cell Sci 2000; 113: 1525-1534.
31. HOROWITZ JR, RIVARD A, VAN DER ZEE R, HARIAWALA M. SHERIFF DD et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2793-2800.
32. KUENEN BC, LEVI M, MEIJERS JC, KAKKAR AK, VAN HINSBERGH VW et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002; 22: 1500-1505.
33. CINES DB, POLLAK ES, BUCK CA, LOSCALZO J, ZIMMERMAN GA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.